Takara Bio Inc.
Stock Price Chart
2026/06/05 UpdatedPrice Trend
2026/06/05 UpdatedPrice & Trading Details
2026/06/05 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/06/05Earnings Calendar
Updated 2026/06/05Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2025/05/12 | ¥16.10 | ¥20.10 | +24.8% |
| 2025/02/13 | ¥-6.00 | ¥-15.71 | -161.8% |
| 2024/11/08 | ¥1.10 | ¥12.96 | +1,078.2% |
| 2024/08/07 | ¥-4.50 | ¥-8.70 | -93.3% |
Shareholder Composition
Updated 2026/06/05Major Holders
Updated 2026/06/05| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
662.3K | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
416.4K | 0.00% | |
|
DFA INVESTMENT TRUST CO-The Japanese Small Company Series
|
221.9K | +32.00% | |
|
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard FTSE All-World ex-US Small-Cap
|
171.6K | 0.00% | |
|
Dimensional ETF Trust-Dimensional International Small Cap ETF
|
160.9K | +12.75% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT.
|
109.2K | -34.96% |
Dividend History
Updated 2026/06/04| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥17 | 0.0% |
| 2024 | ¥17 | -59.5% |
| 2023 | ¥42 | +27.3% |
| 2022 | ¥33 | +266.7% |
| 2021 | ¥9 | - |
Financial Performance
2026/06/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥67,699M | ¥78,142M | ¥43,505M | ¥45,039M |
| Gross Profit | ¥49,211M | ¥44,765M | ¥26,908M | ¥26,067M |
| Operating Income | ¥28,904M | ¥20,546M | ¥3,004M | ¥2,266M |
| Pretax Income | ¥27,555M | ¥21,248M | ¥2,876M | ¥2,017M |
| Net Income | ¥19,849M | ¥16,012M | ¥1,480M | ¥1,041M |
| EPS | ¥164.84 | ¥132.97 | ¥12.30 | ¥8.65 |
| Operating Margin | 42.69% | 26.29% | 6.90% | 5.03% |
| Balance Sheet | ||||
| Total Assets | ¥115,712M | ¥129,202M | ¥121,252M | ¥125,334M |
| Total Equity | ¥95,871M | ¥112,217M | ¥111,503M | ¥115,498M |
| Total Liabilities | ¥19,841M | ¥16,985M | ¥9,749M | ¥9,836M |
| Cash | ¥23,633M | ¥51,847M | ¥35,416M | ¥29,549M |
| Interest-bearing Debt | ¥1,047M | ¥972M | ¥968M | ¥1,101M |
| Equity Ratio | 82.85% | 86.85% | 91.96% | 92.15% |
| D/E Ratio | 0.01 | 0.01 | 0.01 | 0.01 |
| Cash Flow | ||||
| Operating CF | ¥6,985M | ¥36,897M | ¥1,711M | ¥5,844M |
| Investing CF | -¥7,071M | -¥6,693M | -¥13,043M | -¥10,912M |
| Financing CF | -¥2,070M | -¥4,119M | -¥5,233M | -¥2,256M |
| Free CF | -¥5,554M | ¥31,015M | -¥11,161M | -¥4,434M |
| Efficiency | ||||
| ROE | 20.70% | 14.27% | 1.33% | 0.90% |
| ROA | 17.15% | 12.39% | 1.22% | 0.83% |
Latest IR Information
-
【Takara Bio】 Notice of Share Consolidation and Delisting | May 2026
Takara Bio plans to execute a share consolidation on May 20, 2026, and will delist from the stock exchange on the same day. The consolidation ratio is set at 15,332,374 shares to 1 share, reducing the issued shares from 120,415,300...
Read more -
Notice Regarding Cancellation of Treasury Stock
Takara Bio Inc. announced it plans to cancel 300 shares of treasury stock held as of June 15, 2026.
Read more -
Notice of Extraordinary General Meeting of Shareholders Regarding Share Consolidation, Abolition of the Designation of Number of Shares per Unit, and Partial Amendment of the Articles of Incorporation
Takara Bio Inc. plans to implement a share consolidation at the extraordinary general meeting of shareholders on May 20, 2026, consolidating 15,332,374 shares into one share, reducing the number of issued shares from 120,415,294 shares to 6 shares. The tender...
Read more -
Notice Regarding the Result of the Tender Offer for Our Common Shares by Our Parent Company Takara Holdings Inc.
Takara Holdings Inc. conducted a tender offer for 47,065,467 common shares of Takara Bio Inc. from February 16 to April 6, 2026, and purchased all 31,733,101 shares tendered.
Read more -
Notice Regarding the Setting of the Record Date for the Extraordinary General Meeting of Shareholders
Notification that the record date to determine shareholders eligible to exercise voting rights for the extraordinary general meeting of shareholders scheduled for late May 2026 has been set as April 14, 2026.
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥1,900
Rating Score: - (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Takara Bio Inc., together with its subsidiaries, engages in the businesses of reagents, equipment, contract services, and genetic medicine in Japan, China, the rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including reagents needed for genetic and cellular research, PCR instruments, cellular analysis devices, and in vitro diagnostics for COVID-19 testing. It also provides contract services related to regenerative medicine products and contract services related to gene analysis and testing. In addition, the company is involved in commercialization of its proprietary platform technology for biologics development; development, manufacture, and sale of manufacture ancillary materials, such as RetroNectin that is used in the manufacture of gene therapy product; application for marketing authorization of NY-ESO-1 siTCR gene therapy product; and development of JAK/STAT technology suitable for CAR gene therapy and applied development of CereAAV, a brain-tropic adeno-associated virus vector. It provides its products and services through sales agents or directly to its customers. The company was incorporated in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.
